Compare ANVS & CFND Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | ANVS | CFND |
|---|---|---|
| Founded | 2008 | N/A |
| Country | United States | |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | |
| Sector | Health Care | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 111.3M | 27.4M |
| IPO Year | 2019 | 2025 |
| Metric | ANVS | CFND |
|---|---|---|
| Price | $2.68 | $3.77 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 2 | 0 |
| Target Price | ★ $13.50 | N/A |
| AVG Volume (30 Days) | ★ 340.4K | 34.0K |
| Earning Date | 01-01-0001 | N/A |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 62.92 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $1.11 | $3.80 |
| 52 Week High | $5.50 | $9.67 |
| Indicator | ANVS | CFND |
|---|---|---|
| Relative Strength Index (RSI) | 48.34 | 33.79 |
| Support Level | $2.27 | N/A |
| Resistance Level | $2.97 | $5.09 |
| Average True Range (ATR) | 0.20 | 0.18 |
| MACD | 0.07 | 0.01 |
| Stochastic Oscillator | 54.11 | 18.32 |
Annovis Bio Inc is a clinical-stage pharmaceutical company focused on developing and commercializing drugs for the treatment of Parkinson's and Alzheimer's diseases and other neurodegenerative diseases. The pipeline products of the company consists of: Buntanetap for chronic neurodegeneration - including AD and PD; ANVS405 for acute neurodegeneration; and ANVS301 for AD.
C1 Fund Inc is a non-diversified, closed-end management investment company designed to give investors access to the private digital asset ecosystem. Its investment objective is to maximize its portfolio's total return. The fund targets a handpicked portfolio of the late-stage private companies driving the future of digital asset services and technology. It offers early access to the next generation of category-defining companies and aims to bridge the gap between public and private markets and give investors access to the private companies with the safeguards of a NYSE listed fund that is regulated and liquid.